Rigel shares are likely to react positively to acquiring a marketed oncology asset with existing revenue. Watch for HSR clearance and sales trajectory updates in subsequent quarters. The deal adds a near-term revenue stream but carries significant upfront and milestone cash obligations.
Price Chart
Executive Summary
Rigel Pharmaceuticals entered into a worldwide exclusive license agreement with Arvinas and Pfizer for VEPPANUTM (vepdegestrant), an FDA-approved ER+/HER2- breast cancer treatment. Rigel will pay $70M upfront, $15M on transition completion, up to $320M in milestones, plus tiered royalties, and reimburse up to $40M in development costs. The deal provides Rigel with a commercial-stage asset, representing a significant pipeline and revenue opportunity.
Key Financial Metrics
Key Facts
- Rigel obtains exclusive worldwide license for VEPPANU (vepdegestrant), an approved ER+/HER2- breast cancer drug.
- Upfront payment of $70 million, plus $15 million upon successful transition completion.
- Up to $320 million in regulatory and sales milestone payments ($60M regulatory, $260M sales).
- Tiered royalties on net sales from mid-teens to mid-twenties percentages.
- Rigel to reimburse licensors up to $40 million for development costs related to transition activities.
- Agreement subject to HSR antitrust waiting period.
Financial Impact
Upfront $70M cash payment (~14% of market cap) plus $15M near-term, $40M development reimbursement, and up to $320M contingent milestones over life of royalty term.
Risk Factors
- Execution risk in transitioning manufacturing and commercial activities from Pfizer.
- Sales of VEPPANU may not meet thresholds to trigger milestones or cover upfront costs.
- Potential integration challenges and dilution from future capital raises to fund payments.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001034842-26-000038 |
| Document: 0001034842-26-000038-index.html | 0001034842-26-000038 |
| Document: 0001034842-26-000038.txt | 0001034842-26-000038 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $40.48 $49.42 | ▲ +22.09% | ▲ +22.69% | $46.50 (+14.87%) |
Jun 17, 2026 15w ago | 8-K | $32.91 $41.67 | ▲ +26.62% | ▲ +26.09% | $46.50 (+41.29%) |
Jun 11, 2026 16w ago | Institutional Cluster | $32.08 $43.76 | ▲ +36.41% | ▲ +34.52% | $46.50 (+44.95%) |
May 20, 2026 19w ago | 8-K | $29.19 $35.78 | ▲ +22.58% | ▲ +22.24% | $46.50 (+59.30%) |
May 12, 2026 20w ago | 8-K | $32.13 $32.08 | ▼ −0.16% | ▲ +0.46% | $46.50 (+44.72%) |
May 5, 2026 21w ago | 8-K | $26.67 $30.30 | ▼ −13.61% | ▼ −10.83% | $46.50 (−74.35%) |
Apr 21, 2026 23w ago | 8-K | $30.47 $28.30 | ▲ +7.12% | ▲ +10.29% | $46.50 (−52.61%) |
Apr 3, 2026 25w ago | DEFA14A | $27.36 $29.54 | ▲ +7.97% | ▼ −1.01% | $46.50 (+69.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access